Library · Reproductive · Treatment of metastatic castration-resistant prostate cancer
Pluvicto (Lutetium Lu 177 vipivotide tetraxetan)
177Lu-PSMA-617, Lutetium (177Lu) vipivotide tetraxetan, LuPSMA
A targeted radiopharmaceutical pairing a PSMA-binding molecule with radioactive lutetium-177, approved by the FDA in 2022 for PSMA-positive metastatic castration-resistant prostate cancer after prior treatment. It marked a major step for precision nuclear medicine in oncology.
Research score 92/100. Reference only, not a dose.
Boxed warning: Risk of major cardiovascular events
- Anti-cancer
- Hormone Regulation
- DNA Repair
- Anti-inflammatory
- Inflammation Resolution
- US status
- FDA Approved
- Approval
- FDA + EMA Approved
- Evidence
- Extensive Human Studies
- Research score
- 92 / 100
- Indication
- Prostate Cancer
- Origin
- Germany
- Source category
- Reproductive System
- Status group
- Approved / prescription
Mechanism
Binds PSMA overexpressed on prostate cancer cells, delivering localized beta radiation with about a 1 mm range that causes DNA breaks and cell death in tumor and nearby cells, with a stable chelator preventing systemic release of the isotope.
Safety file
Good tolerability profile.
- Fatigue
- Dry mouth
- Nausea
- Anemia
- Decreased appetite
- Low platelet counts
- Constipation